ERBB2 and breast cancer: Another report found significant association between a panel of 3 ci-miRNAs (ci-miRNA-21, ci-miRNA-210, and ci-miRNA-373) and poor clinical outcome in HER2-positive non metastatic breast cancer patients treated with neo-adjuvant therapy, or adjuvant therapy ± trastuzumab [117].